Difference between revisions of "Tranylcypromine-agomelatine"
From Psychiatrienet
(Created page with '{{ Drugswitch | from = tranylcypromine | to = agomelatine | stop = * '''Before day 0:''' gradually reduce dosage of tranylcypromine to a maximum of 40 mg/day, when this dosag...') |
|||
| Line 9: | Line 9: | ||
| start = | | start = | ||
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day. | * '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day. | ||
| − | * '''Day 15:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. }} | + | * '''Day 15:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day. |
| + | | info = | ||
| + | * Tranylcypromine has to be phased out to avoid withdrawal symptoms. | ||
| + | * Because tranylcypromine is a irriverible MAO inhibitor, the activity of MAO enzymes will be normal after two weeks. | ||
| + | }} | ||
Revision as of 08:58, 7 May 2009
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Switch medication from tranylcypromine to agomelatine.[1] [2]
Stop tranylcypromine - Before day 0: gradually reduce dosage of tranylcypromine to a maximum of 40 mg/day, when this dosage is > 40 mg/day.
- Day 1: reduce dosage of tranylcypromine to 20 mg/day.
- Day 8: reduce dosage of tranylcypromine to 10 mg/day.
- Day 15: stop administration of tranylcypromine.
Start agomelatine- Day 1: simultaneously start administration of agomelatine in a dosage of 25 mg/day.
- Day 15: only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.
More information- Tranylcypromine has to be phased out to avoid withdrawal symptoms.
- Because tranylcypromine is a irriverible MAO inhibitor, the activity of MAO enzymes will be normal after two weeks.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
